Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals` VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme
GBM Agile is the next generation of clinical trial - where multiple drugs are tested against a common control arm, instead of each trial having it's own control arm. They selected Val-083 to test in one of the arms of the trial. Val-083 is an experimental chemotherapy, similar to Temodar but it works on a different area of the DNA so the MGMT repair enzyme can not undo the damage it does to the tumor. In theory, it should not matter if the MGMT is methylated or unmethylated. With Temodar, if your MGMT is unmethylated, there is a much less chance that it will help. This is probably the best and fastest path to FDA approval for Val-083. I wish them luck.
Posted on: 06/13/2020
Click HERE to return to brain tumor news headlines